Company intelligence / Profile preview
QureBio Ltd.
Shanghai, Shanghai, Chinaqurebio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
QureBio’s lead program Q‑1802—a bispecific antibody targeting Claudin18.2 and PD-L1—has demonstrated excellent safety, tolerability, and preliminary anti-tumor activity in Phase I trials for relapsed/refractory solid tumors. The company has multiple additional programs at preclinical or IND stages targeting cancer and inflammation.
- Therapeutic areas
- OncologyImmunologyMetabolic Disorders
- Modalities
- Bispecific antibodiesMonoclonal antibodies (mAbs)Fusion proteinsTrispecific antibodies
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
BRL MedicineBioMapPrecision ScientificHengrui Pharmaceuticalsongoing collaborations with industry partners for novel therapeutics development.
Beyond the preview
Go deeper on QureBio Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QureBio Ltd..